Literature DB >> 18279175

SMAP29 congeners demonstrate activity against oral bacteria and reduced toxicity against oral keratinocytes.

P L Weistroffer1, S Joly, R Srikantha, B F Tack, K A Brogden, J M Guthmiller.   

Abstract

INTRODUCTION: Cathelicidins are antimicrobial peptides found in epithelial and mucosal tissues as well as the secondary granules of neutrophils. SMAP29, a sheep cathelicidin, has differential antimicrobial properties against various pathogens, including periodontal organisms. The purpose of this study was to evaluate the antimicrobial properties and cytotoxicity of SMAP29, SMAP28, and three congeners (SMAP18A, SMAP18D, and SMAP14A).
METHODS: The peptides at concentrations ranging from 0.25 to 250 microg/ml were tested for their activity against multiple strains of Streptococcus mutans, Streptococcus sanguis, Actinomyces israelii, Actinomyces naeslundii, Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum, Peptostreptococcus micros, and Porphyromonas gingivalis using a radial diffusion assay. Cytotoxicity of keratinocytes was evaluated by measuring lactate dehydrogenase release after incubation with the individual peptides.
RESULTS: SMAP28, thought to be the biologically active peptide, was the most potent antimicrobial (range of minimum inhibitory concentrations 0.06-7.03 microg/ml, P < 0.05); however, the activity of SMAP28 and SMAP29 was strongly associated (r = 0.933). The congeners also demonstrated antimicrobial activity against the bacteria tested (range of minimum inhibitory concnetrations 0.21-79 microg/ml). Overall, F. nucleatum was the most susceptible organism, while P. gingivalis was the least susceptible. Keratinocyte cytotoxicity was dependent on peptide length and dose. SMAP28 was the most cytotoxic, while SMAP14A was the least cytotoxic.
CONCLUSION: The antimicrobial activities against oral microorganisms and the minimal toxicity seen in this study suggest that the congeners of SMAP29 may serve as an alternative to traditional antibiotics in the prevention and treatment of periodontal and other oral diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279175     DOI: 10.1111/j.1399-302X.2007.00389.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  6 in total

1.  Communication: Antimicrobial Activity of SMAP28 with a Targeting Domain for Porphyromonas gingivalis.

Authors:  Carol L Bratt; Karl G Kohlgraf; Katie Yohnke; Colleen Kummet; Deborah V Dawson; Kim A Brogden
Journal:  Probiotics Antimicrob Proteins       Date:  2010-03-01       Impact factor: 4.609

Review 2.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

3.  Promise of Combining Antifungal Agents in Denture Adhesives to Fight Candida Species Infections.

Authors:  Jorge L Garaicoa; Carol L Fischer; Amber M Bates; Julie Holloway; Gustavo Avila-Ortiz; Janet M Guthmiller; Georgia K Johnson; Clark Stanford; Kim A Brogden
Journal:  J Prosthodont       Date:  2016-11-21       Impact factor: 2.752

Review 4.  Targeted antimicrobial therapy in the microbiome era.

Authors:  V N Stone; P Xu
Journal:  Mol Oral Microbiol       Date:  2017-08-01       Impact factor: 3.563

Review 5.  Interconnections Between the Oral and Gut Microbiomes: Reversal of Microbial Dysbiosis and the Balance Between Systemic Health and Disease.

Authors:  Brandon Khor; Michael Snow; Elisa Herrman; Nicholas Ray; Kunal Mansukhani; Karan A Patel; Nasser Said-Al-Naief; Tom Maier; Curtis A Machida
Journal:  Microorganisms       Date:  2021-02-26

6.  Oral mucosal lipids are antibacterial against Porphyromonas gingivalis, induce ultrastructural damage, and alter bacterial lipid and protein compositions.

Authors:  Carol L Fischer; Katherine S Walters; David R Drake; Deborah V Dawson; Derek R Blanchette; Kim A Brogden; Philip W Wertz
Journal:  Int J Oral Sci       Date:  2013-07-19       Impact factor: 6.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.